Gluten immunogenic peptide (GIP) (GIP)

Gluten immunogenic peptides (GIPs) are protein fragments derived from the incomplete digestion of gluten proteins (gliadins and glutenins) found in wheat, barley, and rye. Due to their unusually high proline and glutamine content, these peptides are resistant to breakdown by human gastric, pancreatic, and intestinal proteases [4, 9, 11]. In individuals with celiac disease, GIPs cross the intestinal barrier and undergo deamidation by tissue transglutaminase 2 (tTG2), which significantly enhances their binding affinity to HLA-DQ2 or HLA-DQ8 molecules on antigen-presenting cells [6, 12, 15]. This presentation triggers a potent T-cell-mediated immune response, resulting in chronic intestinal inflammation, villous atrophy, and malabsorption [1, 4, 12]. Pharmacological strategies target GIPs through oral enzyme replacement therapies, such as latiglutenase and TAK-062, which are designed to hydrolyze the peptides into non-immunogenic fragments before they reach the small intestine [1, 6, 9]. Furthermore, the detection of GIPs in stool and urine serves as a highly specific and non-invasive biomarker for monitoring dietary adherence and evaluating the efficacy of investigational celiac disease treatments [8, 10, 13].

Other names

Gliadin-derived peptidesGluten peptidesToxic gluten peptides33-mer peptide26-mer peptideProlamin-derived peptides

Enzymatic hydrolysis of proline-rich and glutamine-rich sequences to neutralize immunogenicity; sequestration by polymeric binders to prevent intestinal absorption.